Mocravimod (KRP203)
Acute Myeloid Leukemia (AML) maintenance post-allogeneic hematopoietic cell transplantation (allo-HCT)
Key Facts
About Priothera
Priothera is a private, clinical-stage biotech developing mocravimod, a sphingosine-1-phosphate (S1P) receptor modulator, to improve outcomes in blood cancer patients undergoing stem cell transplants. The company's core innovation is a potential best-in-class therapy designed to decouple the beneficial graft-versus-leukemia (GvL) effect from the harmful graft-versus-host disease (GvHD), addressing a major unmet need in acute myeloid leukemia (AML) and other hematological malignancies. With promising early clinical data, Priothera is advancing its lead program into a pivotal Phase 3 study (MO-TRANS) for AML patients post-transplant, positioning itself to transform the standard of care in a high-mortality setting. The company is led by a seasoned team with deep experience in immunology and drug development.
View full company profile